Plasma-derived therapies play a critical role in modern healthcare, providing life-saving treatments for patients with immune deficiencies, bleeding disorders, rare diseases, and other serious conditions. As demand for these therapies continues to grow, manufacturers face increasing pressure to improve process efficiency, strengthen product safety, and maintain reliable supply.

In this environment, regulatory confidence is just as important as purification performance.

For plasma fractionators and biopharmaceutical manufacturers, chromatography technologies with an established regulatory track record can help reduce risk, support process validation, and enable long-term manufacturing success. Astrea Bioseparations' plasma heritage spans more than three decades of chromatography development, industrialization, and regulatory integration, helping manufacturers modernize plasma purification while operating within validated and licensed manufacturing frameworks.

The evolution of plasma purification

Traditional plasma fractionation has historically relied on ethanol precipitation processes developed through the Cohn fractionation method. While these approaches remain foundational to plasma processing, the industry has increasingly adopted chromatography technologies to improve selectivity, recovery, and process control.

Chromatographic purification introduced a new approach to plasma processing by enabling selective adsorption rather than relying solely on precipitation-based recovery. This transition helped manufacturers improve yields while preserving the regulatory foundations of established plasma products.

Today, many plasma purification processes incorporate hybrid workflows that combine traditional fractionation techniques with advanced chromatography steps. These approaches provide greater control over impurity removal, improved consistency, and enhanced process flexibility.

Advancing IVIG purification through chromatography

Intravenous immunoglobulin (IVIG) remains one of the most important plasma-derived therapeutics worldwide. As manufacturing requirements have evolved, chromatography has become an increasingly valuable tool for improving purification efficiency and product quality.

Chromatographic technologies developed within Astrea Bioseparations' heritage have supported the purification of IgG from Cohn fractions II and III, enabling improved selectivity and integration with advanced downstream purification processes.

Mixed-mode chromatography technologies such as MiMode PuraBead® HL3 were engineered to meet the demands of large-scale plasma manufacturing, offering:

• High IgG purity
• Effective removal of albumin and IgM impurities
• Industrial robustness
• Caustic stability for repeated sanitization
• Compatibility with GMP manufacturing environments

These developments helped reduce dependence on solvent-intensive fractionation processes while supporting modern chromatography-based IVIG manufacturing strategies.

Improving IVIG safety through isoagglutinin reduction

One of the most significant advances in IVIG purification has been the development of dedicated immunoaffinity chromatography technologies for isoagglutinin removal.

Isoagglutinins, including anti-A and anti-B antibodies, require careful control during IVIG manufacturing to support product safety and meet regulatory expectations.

Astrea Bioseparations helped pioneer this area through the development of IsoClear® XT, an immunoaffinity chromatography resin specifically designed for isoagglutinin polishing.

By selectively targeting anti-A and anti-B antibodies while preserving overall IgG yield, immunoaffinity polishing enables manufacturers to:

• Improve batch-to-batch consistency
• Achieve tighter control of isoagglutinin titers
• Strengthen product safety profiles
• Support regulatory compliance
• Maintain established licensed manufacturing processes

The adoption of these technologies contributed to measurable reductions in hemolysis-related adverse events associated with IVIG therapy, demonstrating how targeted chromatographic purification can directly impact patient outcomes.

The importance of albumin purification in plasma manufacturing

Human serum albumin (HSA) remains the highest-volume plasma protein produced globally and is essential to both therapeutic supply and fractionation economics.

Chromatographic albumin purification introduced new opportunities for plasma manufacturers to optimize recovery and improve operational efficiency. Technologies such as Mimetic Blue® were developed to support selective albumin capture and removal while providing flexibility within established plasma fractionation workflows.

Beyond purification performance, chromatography-based albumin capture offers several operational advantages:

• Improved process flexibility
• Enhanced plasma protein recovery economics
• Incremental process modernization
• High durability and long operational lifetimes
• Compatibility with validated GMP manufacturing processes

These benefits have made chromatography an important strategic tool for improving facility efficiency and long-term supply resilience.

Chromatography technologies embedded in approved therapies

Perhaps the strongest demonstration of a purification technology's value is its successful integration into licensed therapeutic manufacturing.

Over several decades, Astrea Bioseparations and its predecessor organizations developed multiple chromatography adsorbents specifically designed for plasma purification cascades. These technologies supported numerous clinical development programs and commercial manufacturing processes.

One notable milestone was the development of chromatography technologies that contributed to the manufacture of the first FDA-approved intravenous plasminogen therapy for patients with plasminogen deficiency.

The approved therapy continues to utilize chromatography products developed within the Astrea platform, demonstrating direct integration of these purification technologies into a licensed rare disease treatment.

For manufacturers operating in highly regulated environments, this type of regulatory and commercial experience provides confidence that purification technologies can support both product quality and long-term manufacturing requirements.

Supporting plasma safety and supply resilience

Plasma-derived therapies depend on a limited and valuable raw material supply. As global demand increases, manufacturers must maximize yield while maintaining stringent safety standards.

Chromatography has become a critical enabler of this balance by providing more targeted impurity removal, improved process control, and scalable purification performance.

Astrea Bioseparations' work has also extended into plasma safety initiatives, including affinity-based approaches designed to support pathogen and prion reduction strategies. These efforts have helped shape evolving plasma safety paradigms across the industry.

For rare diseases where plasma-derived proteins may represent the only available treatment option, robust purification technologies play an essential role in ensuring reliable patient access.

Building the future of plasma purification

The plasma industry continues to evolve, but the need for reliable, regulatory-ready purification technologies remains constant.

Today, Astrea Bioseparations continues to support plasma fractionators worldwide with advanced chromatography resins, purification technologies, and application expertise tailored to regulated biomanufacturing environments.

By combining decades of plasma purification experience with ongoing innovation, manufacturers can modernize operations, improve process performance, and maintain confidence in the safety and consistency of life-saving plasma-derived therapeutics.

Partner with plasma purification experts

Whether you are optimizing an existing plasma fractionation process or developing the next generation of plasma-derived therapeutics, selecting technologies with a proven regulatory track record can help reduce risk and accelerate success.

Contact Astrea Bioseparations to learn how our chromatography solutions can support your plasma purification workflow.